In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections

A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized patients with suspected/confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSIs). Evaluating...

Descripción completa

Detalles Bibliográficos
Autores principales: Scangarella-Oman, Nicole E., Ingraham, Karen A., Tiffany, Courtney A., Tomsho, Lynn, Van Horn, Stephanie F., Mayhew, David N., Perry, Caroline R., Ashton, Theresa C., Dumont, Etienne F., Huang, Jianzhong, Brown, James R., Miller, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038298/
https://www.ncbi.nlm.nih.gov/pubmed/31818823
http://dx.doi.org/10.1128/AAC.01302-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038298/
https://www.ncbi.nlm.nih.gov/pubmed/31818823
http://dx.doi.org/10.1128/AAC.01302-19

Ejemplares similares